에 대한 최신 뉴스 Doximity (NYSE:DOCS) 주식

DOXIMITY INC-CLASS A

Doximity

Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.

Comments From Palantir’s CTO

Equities

Large Cap

News

Movers

Trading Ideas

AFRM

DOCS

EXPE

MPWR

PINS

PLTR

SMCI

SPOT

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 팔란티어 테크놀로지스(NASDAQ:PLTR)의 주식은 회사가 강력한 4분기 재무 결과를 발표한 후 34.38% 급등했다. 여러 애널리스트들도 목표 주가를 상향 조정했다.

팔란티어, 슈퍼 마이크로 컴퓨터 및 스포티파이 등 지난주 상승한 10개 대형주 (2월 3일-2월 7일)

DRI, Darden

BIRK

CHWY

KVYO

NBIX

TEVA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 테바 파마수티컬스(NYSE:TEVA)의 주식은 회사와 사노피 SA(NASDAQ:SNY)가 궤양성 대장염 및 크론병에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.

테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)

trump-chart-shutter

ALAB

AXON

COIN

HOOD

RDDT

TSLA

이들 10개 대형주는 도널드 트럼프가 47대 대통령 선거에서 승리한 지난주에 가장 좋은 성과를 냈다. 1. 앱러빈(NASDAQ:APP)의 주식은 3분기 실적 발표 후 82.27% 급등했다. 여러 애널리스트들이 주가 전망을 상향 조정했다.

도널드 트럼프 승리 주(11월 4일-8일): 이들 10개 대형주는 가장 큰 폭의 상승 기록

Doximity Inc

Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) activated its long-anticipated Pectra upgrade on May 7, marking a pivotal step in the network&#8217;s evolution since the <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37667987/ethereum-dencun-upgrade-drops-layer-2-fees-by-99">Dencun fork last year.</a>
The upgrade went live at 6:05 a.m. ET, with finality confirmed just over ten minutes later.
Pectra introduces sweeping changes across the Ethereum protocol, most notably EIP-7702, a feature that redefines how externally owned accounts (EOAs) interact with smart contracts. 
For the first time, regular user wallets can execute contract logic while maintaining the same address, paving the way for smarter, more flexible user accounts.
EIP-7702 is seen as foundational for full account abstraction, where users can batch transactions, skip manual token approvals and interact seamlessly across apps.
The upgrade also brings changes to Ethereum's validator model with EIP-7251, lifting the staking cap from 32 to 2,048 ETH per validator. 
This allows larger stakers to consolidate capital more efficiently, improving protocol operations and reward distribution. 
Additionally, EIP-7691 doubles the number of blobs per block from three to six, improving Layer-2 throughput and lowering rollup transaction costs.
Still, the upgrade isn't without its tradeoffs.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45253032/anthony-scaramucci-gives-donald-trump-b-or-a-on-crypto-but-warns-presidential-meme-coin-defi-project-risk-derailing-policy-progress">Anthony Scaramucci Gives Donald Trump &#8216;B+ Or A-&#8216; On Crypto But Warns Presidential Meme Coin, DeFi Project Risk Derailing Policy Progress</a>
In a note sent to Benzinga, Muriel Médard, MIT professor and co-founder of Optimum, pointed out a rising bottleneck: network bandwidth. 
"With Pectra live, bandwidth has become the binding constraint, especially as blobs must be gossiped across the peer-to-peer layer," she said. "Ethereum's ability to propagate data efficiently and predictably will define how far it can scale."
She added that as blob sizes grow, reducing variability, not just increasing average bandwidth, is essential. 
"Unpredictability undermines reliability across rollups and apps. This is now core infrastructure," Médard stressed.
Security experts have also raised concerns about EIP-7702's deeper implications. 
In a blog <a href="https://www.certik.com/resources/blog/pectras-eip-7702-redefining-trust-assumptions-of-externally-owned-accounts">post</a>, CertiK, a blockchain security firm, warned that the upgrade breaks a longstanding assumption that EOAs cannot run contract code. 
As a result, contracts that rely on outdated patterns like <code>tx.origin == msg.sender</code> for reentrancy or flash loan protection may be vulnerable.
"The trust model has changed," CertiK said in a report. "EOAs can now execute logic, creating new risk vectors in contracts that didn't anticipate this behavior."
The firm cited recent activity on Binance Smart Chain, which adopted a similar upgrade called Pascal in March, where it observed suspicious transactions exploiting these assumptions.
Developers are being urged to update their codebases and abandon any logic that treats EOAs as inherently passive. 
Instead, industry-standard protections like reentrancy guards and proper logical constraints should replace fragile assumptions.
Despite these growing pains, the Pectra upgrade is widely seen as a necessary milestone. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45248407/rabbitx-founder-eyes-real-world-assets-and-liquidity-tokenization-as-the-future-of-perpetual-trading">RabbitX Founder Eyes Real-World Assets And Liquidity Tokenization As The Future Of Perpetual Trading</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

Ethereum's Pectra Upgrade Goes Live: Here's What You Need To Know

WIIM

PKOH

Park-Ohio Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 sales guidance with its midpoint below estimates.

Seagate Technology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>)&nbsp;is amid efforts to develop a <a target="_blank" href="https://www.benzinga.com/topic/seagate-technology" rel="noreferrer noopener">100-terabyte hard drive</a> by 2030.
Seagate&#8217;s chief commercial officer, BS Teh, <a target="_blank" href="https://www.cnbc.com/2025/05/07/seagate-to-triple-hard-drive-capacity-by-2030-to-meet-ai-demand.html" rel="noreferrer noopener">told</a> CNBC on Wednesday that the data storage firm aims to launch a drive with about three times the capacity of its top-notch hard drives by 2030.
The largest hard disk drive Seagate currently produces is the 36-terabyte Exos M model.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45080030/western-digital-refocuses-after-post-sandisk-spin-off-as-analyst-highlights-ai-led-hdd-growth" rel="noreferrer noopener">Western Digital Refocuses Post-SanDisk Spin-Off As Analyst Highlights AI-Led HDD Growth</a>
Teh expressed conviction in strong demand, underlining the need for the 100-terabyte hard drive. Teh also said Seagate is amid efforts to counter climate concerns surrounding AI&#8217;s energy demands.
Teh expressed conviction in hard disk drive prospects, citing it as a much more sustainable device technology.
Big Tech&#8217;s 2025 <a target="_blank" href="https://www.benzinga.com/markets/25/02/43962882/meta-gears-up-for-ai-dominance-with-200-billion-data-center-project-report" rel="noreferrer noopener">AI infrastructure investments</a> included Amazon.com Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) $100 billion, followed by Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) at $80 billion each, and Meta committing over $60 billion.
Microsoft expects to spend $80 billion on data centers&nbsp;in fiscal 2025.
February reports indicated Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is in talks to build an AI data center campus that could exceed $200 billion in costs.
Seagate Technology Holdings stock gained close to 9% year-to-date. It reported <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/45116667/whats-going-on-with-seagate-technology-stock-wednesday" rel="noreferrer noopener">third-quarter sales</a> of $2.16 billion (versus $1.66 billion Y/Y), missing the analyst estimate of $2.31 billion. It reported adjusted earnings per share of $1.90, missing the analyst estimate of $2.09.
Seagate expects fourth-quarter revenue of&nbsp;$2.25 billion-$2.55 billion, versus the&nbsp;$2.43 billion estimate, and adjusted earnings of $2.20-$2.60&nbsp;per share, versus the&nbsp;$2.20&nbsp;analyst estimate.
Price Action: STX stock is up 1.16% at $94.99 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45237744/on-semiconductor-sees-green-shoots-in-industrial-auto-shift-as-analysts-stay-cautious" target="_blank" rel="noreferrer noopener">ON Semiconductor Powers Through Expectations, But Analysts Dial Down Targets On Margin Squeeze</a></li>
</ul>
Photo via Shutterstock

Tech

Media

AMZN

GOOG

GOOGL

MSFT

Seagate Bets On Mega-Sized, Sustainable Drives As AI Sparks Record Data Demand

Energizer Holdings shares are trading lower after Canaccord Genuity maintained a Hold rating on the stock and lowered its price target from $31 to $27. Also, UBS maintained a Neutral rating on the stock and lowered its price target from $28 to $26.

<a href="https://www.gov.uk/government/news/mhra-approves-teprotumumab-as-the-first-uk-treatment-for-adults-with-moderate-to-severe-thyroid-eye-disease-ted#:~:text=As%20with%20all%20products%2C%20the%20MHRA">https://www.gov.uk/government/news/mhra-approves-teprotumumab-as-the-first-uk-treatment-for-adults-with-moderate-to-severe-thyroid-eye-disease-ted#:~:text=As%20with%20all%20products%2C%20the%20MHRA</a>
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 7 May 2025, approved teprotumumab (Tepezza). This is the first medicine to be licensed in the UK for adult patients with moderate to severe Thyroid Eye Disease (TED).&nbsp;
TED is an autoimmune condition where the immune system attacks the muscles and fat around the eyes.&nbsp; In TED, the immune system activates a protein called IGF-1R, causing inflammation and swelling in these tissues. Tepezza is designed to bind to IGF-1R to block its activation and signalling.&nbsp;
This medicine is administered via an intravenous drip directly into a vein by a healthcare professional.

Biotech

General

AMGN

MHRA Approves Teprotumumab As The First UK Treatment For Adults With Moderate To Severe Thyroid Eye Disease

Steven Madden Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) shares are <a href="https://www.benzinga.com/movers">trading higher on Wednesday</a> after the first-quarter FY25 earnings.
The company reported <a href="https://www.benzinga.com/pressreleases/25/05/g45248046/steve-madden-announces-first-quarter-2025-results">first-quarter revenue growth</a> of 0.2% year-on-year to $551.38 million, missing the analyst consensus estimate of $557.34 million.
Revenue for the wholesale business increased 0.2% to $439.3 million, and Direct-to-Consumer revenue fell 0.2% to $112.1 million.
Gross profit margin expanded 20 basis points Y/Y to 40.9%.
Also Read: <a href="https://www.benzinga.com/25/05/45237060/despite-nikes-executive-overhaul-ongoing-challenges-persist-says-analyst">Nike Revamps C-Suite, &#8216;Win Now&#8217; Strategy Faces Profit Pressure: Analyst</a>
The operating margin was 9.7%, and operating income for the quarter was $53.5 million. Adjusted EPS of 60 cents<a href="https://www.benzinga.com/earnings"> beat the consensus </a>estimate of 45 cents.
Steven Madden held $114.7 million in cash and equivalents as of March 31, 2025. Cash used in operating activities for the quarter totaled $(18.8) million.
The company&#8217;s board of directors approved a quarterly cash dividend of 21 cents per share. The dividend is payable on June 20, 2025, to stockholders of record as of the close of business on June 9, 2025.
The company ended the quarter with 314 brick-and-mortar retail stores and five e-commerce websites.
Edward Rosenfeld, chairman and CEO, commented, &#8220;Looking ahead, we face meaningful near-term headwinds and heightened uncertainty due to the impact of new tariffs on goods imported into the U.S.&#8221;
Outlook: The company is withdrawing the 2025 financial guidance provided in its earnings release on Feb. 26, 2025, due to macroeconomic uncertainty related to the impact of new tariffs on goods imported into the U.S.
SHOO Price Action:&nbsp;SHOO shares traded higher by 13.74% at $22.90 at publication on Wednesday.
Read Next: • <a href="https://www.benzinga.com/25/05/45236630/ford-outperforms-in-q1-faces-tariff-challenges-ahead-say-analysts">Ford Outperforms In Q1, Faces Tariff Challenges Ahead, Say Analysts</a>
Photo: Shutterstock

Earnings

Earnings Beats

SHOO

Why Is Steve Madden's Stock Surging Today?

DNOW

DNOW hares are trading lower. The company reported Q1 financial results.

Mattel Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) shares have surged 9% to $17.16 since Tuesday's open, as investors respond to the company's better-than-expected first-quarter earnings.
What To Know: The toymaker posted <a href="https://www.benzinga.com/news/earnings/25/05/45209947/mattel-beats-q1-estimates-pauses-guidance-due-to-tariffs-plans-actions-to-mitigate-cost-impacts">revenue of $827 million</a>, surpassing analyst estimates of $786 million, and reported an adjusted loss of three cents per share—beating the expected 10-cent loss. 
Revenue grew 2% year-over-year, with North America up 3% and international markets up 1%. Gross margin improved to 49.4%, up from 48% a year ago.
CEO Ynon Kreiz described the quarter as strong, citing brand strength and operational resilience. Mattel repurchased $160 million in stock during the quarter and reaffirmed its $600 million buyback target for 2025. 
However, due to macroeconomic volatility and <a href="https://www.benzinga.com/trading-ideas/25/05/45227056/trumps-tariffs-hit-mattels-barbies-will-americans-pay-a-couple-of-bucks-more-as-president-predicts">uncertainty around U.S. tariffs</a>, the company paused its full-year 2025 guidance, noting it will resume once visibility improves.
To counter rising costs, Mattel plans to accelerate supply chain diversification, optimize product sourcing, and raise prices. The company also increased its 2025 cost-saving goal from $60 million to $80 million, reinforcing its focus on efficiency as it navigates a turbulent economic environment.
Read Also: <a href="https://www.benzinga.com/25/05/45256871/energizer-holdings-analysts-cut-their-forecasts-after-q2-results">Energizer Holdings Analysts Cut Their Forecasts After Q2 Results</a>
<h2 class="wp-block-heading">How To Buy MAT Stock</h2>
By now you're likely curious about how to participate in the market for Mattel &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Mattel, which is trading at $17.16 as of publishing time, $100 would buy you 5.83 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MAT has a 52-week high of $22.06 and a 52-week low of $13.94.

Mattel Stock Jumps Following Q1 Results Despite Paused Guidance: What's Going On?

IMCR

Immunocore Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

CRSR

Corsair Gaming shares are trading lower after the company reported mixed Q1 financial results.

In a world increasingly defined by digital assets, borderless banking, and decentralized infrastructure, there is one foundational piece still lagging behind: identity. Who you are, how you prove it, and who controls that information are questions that financial institutions, regulators, and individuals are all racing to answer.
By 2030, the solution may come from an emerging concept already gaining traction in tech circles: self-sovereign identity (SSI). And if you&#8217;re paying attention to the future of finance, it&#8217;s time to understand why this quiet revolution in identity could reshape everything from KYC to asset access.
<h3 class="wp-block-heading">What Is Self-Sovereign Identity (SSI)?</h3>
Self-sovereign identity is a decentralized model that allows individuals to own, manage, and share their digital credentials without relying on a central authority. Instead of logging into banks, brokerages, or apps using credentials stored by third parties, users carry verifiable credentials in a digital wallet they control.
Think of it as a blockchain-secured passport that works across platforms—except you decide who sees what, and when.
SSI enables:
<ul>
<li>Reusable, verified digital credentials (e.g., age, citizenship, income proof)</li>
<li>Privacy-preserving access to services (only the data required is shared)</li>
<li>Elimination of centralized databases vulnerable to hacks</li>
</ul>
<h3 class="wp-block-heading">Why Finance Needs SSI</h3>
Today, financial access is built on a patchwork of identity checks: KYC, AML, credit scoring, and jurisdictional gatekeeping. These systems are:
<ul>
<li>Costly to maintain</li>
<li>Friction-heavy for users</li>
<li>Prone to data breaches</li>
<li>Incompatible across borders</li>
</ul>
SSI fixes these problems by creating a portable, tamper-proof identity layer that can follow the user from country to country, platform to platform.
<h3 class="wp-block-heading">Real-World Applications Already Emerging</h3>
<ul>
<li>KYC Simplification: Instead of uploading documents to every exchange, wallet, or bank, users could submit a single verified credential.</li>
<li>Borderless Finance: SSI enables seamless onboarding for global DeFi platforms without sacrificing compliance.</li>
<li>Reputation Systems: Investors and lenders can assess trustworthiness through on-chain activity, verifiable income, or education records.</li>
<li>Embedded Compliance: Regulators could approve identity schemas without needing constant data collection.</li>
</ul>
<h3 class="wp-block-heading">Who&#8217;s Building It?</h3>
Several players are leading the charge:
<ul>
<li>Microsoft and ConsenSys with their ION project</li>
<li>Sovrin Foundation, focused on decentralized identity networks</li>
<li>World Economic Forum, actively shaping digital ID policy frameworks</li>
<li>European Union, integrating SSI concepts into its eIDAS 2.0 regulation</li>
</ul>
Even the private sector is catching on, with startups integrating digital ID into financial onboarding and tokenized asset platforms.
<h3 class="wp-block-heading">What Investors Should Be Watching</h3>
SSI isn&#8217;t just a technical upgrade. It&#8217;s an investment theme with implications across fintech, cybersecurity, DeFi, and Web3. Key areas to monitor:
<ul>
<li>Wallets and platforms that support verified credentials</li>
<li>SSI integration into tokenized investment platforms</li>
<li>Regulatory clarity on digital ID standards</li>
<li>Companies building identity infrastructure (e.g., verifiers, issuers, networks)</li>
</ul>
<h3 class="wp-block-heading">Final Thought: Identity Is the Next Frontier in Finance</h3>
In the age of tokenized assets, decentralized finance, and programmable money, identity is the glue that holds everything together. Without a trusted, flexible, and user-controlled way to prove who we are, the future of finance remains incomplete.
Self-sovereign identity promises a future where access to capital, credit, and opportunity isn't just efficient. It's fair, secure, and truly global.
By 2030, the winners in finance won&#8217;t just be those who built the best portfolios. They'll be the ones who built trust without borders.

Fintech news covering the emerging Financial Technology services sector

Fintech

Opinion

Why Self-Sovereign ID Will Reshape Finance By 2030

Wedbush analyst Daniel Ives maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Outperform and lowers the price target from $160 to $145.

Price Target

Analyst Ratings

QLYS

Wedbush Maintains Outperform on Qualys, Lowers Price Target to $145

CrowdStrike Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading lower Wednesday after the cybersecurity company announced a new strategic initiatives, including <a href="https://www.benzinga.com/quote/CRWD/earnings">a workforce reduction</a>.
What Happened: CrowdStrike said in a filing Wednesday morning that it adopted a strategic plan to make operations more efficient. The plan includes cutting approximately 500 roles, or 5% of the company&#8217;s global workforce in an effort to operate with discipline as it continues to target scaling up to $10 billion in annual recurring revenue. 
CrowdStrike expects to incur approximately $36 million to $53 million in charges related to the plan. $7 million of those charges are expected to be recognized in the first quarter. The actions are expected to be substantially complete by the end of the second quarter.
CrowdStrike said it expects first-quarter financial results to be in line with or above guidance provided in its <a href="https://www.benzinga.com/news/earnings/25/03/44127302/crowdstrike-q4-earnings-revenue-beat-eps-beat-strong-momentum-shares-slide-on-soft-guidance">fourth-quarter earnings release</a>. CrowdStrike previously guided for first-quarter revenue of $1.1 billion to $1.106 billion, and first-quarter adjusted earnings of 64 cents to 66 cents per share. 
CrowdStrike also reaffirmed its full-year guidance of $4.74 billion to $4.81 billion in revenue and adjusted earnings of $3.33 to $3.45 per share.
CrowdStrike is due to report first-quarter financial results after the market close on June 3. 
CRWD Price Action: <a href="http://benzinga.com/quote/crwd">CrowdStrike shares</a> were down 3.81% at $426.31 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/05/45229107/paul-tudor-jones-warns-ai-could-kill-50-of-humanity-without-proper-oversight-were-creating-something-thats-really-dangerous">Paul Tudor Jones Warns AI Could &#8216;Kill 50% Of Humanity&#8217; Without Proper Oversight: &#8216;We&#8217;re Creating Something That&#8217;s Really Dangerous&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Peter+Vandenbelt">VDB Photos</a>/Shutterstock.

Guidance

CRWD

CrowdStrike Stock Is Sliding Wednesday: What's Going On?

Wedbush analyst Daniel Ives reiterates IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Outperform and maintains $300 price target.

Reiteration

Wedbush Reiterates Outperform on IBM, Maintains $300 Price Target

L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) has outperformed the market over the past 20 years by 2.41% on an annualized basis producing an average annual return of 10.57%. Currently, L3Harris Technologies has a market capitalization of $40.79 billion. 
Buying $1000 In LHX: If an investor had bought $1000 of LHX stock 20 years ago, it would be worth $7,462.04 today based on a price of $218.19 for LHX at the time of writing.
<h3>L3Harris Technologies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746634536_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In L3Harris Technologies 20 Years Ago Would Be Worth Today

MBIA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBI#NYSE">MBI</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-08. Here's what investors need to know before the announcement.
Analysts estimate that MBIA will report an earnings per share (EPS) of $-0.07. 
Investors in MBIA are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.37, which was followed by a 13.53% drop in the share price the next day.
Here's a look at MBIA's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.33</td>
<td>-0.3</td>
<td>-0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.48</td>
<td>0</td>
<td>-2.9</td>
<td>-0.52</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-14.000000000000002%</td>
<td>7.000000000000001%</td>
<td>-8.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746634477_0.png" alt="eps graph" />
<h3>Tracking MBIA's Stock Performance</h3>
Shares of MBIA were trading at $4.64 as of May 06. Over the last 52-week period, shares are down 30.21%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/MBI/earnings">To track all earnings releases for MBIA visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of MBIA's Earnings

In today&#8217;s digital-first economy, the financial sector is undergoing a seismic shift. From personal banking apps to complex trading platforms, financial services are increasingly powered by technology. At the heart of this transformation lies custom fintech software—tailor-made digital solutions designed to meet the specific needs of businesses operating in finance. As a business leader, understanding how and when to invest in such technology is crucial not just for staying competitive, but for ensuring long-term growth and innovation.
This strategic guide aims to demystify the process of investing in custom fintech software. It explores why businesses are moving away from off-the-shelf solutions, the key benefits and risks, how to select the right development partner, and what returns to expect.
<h3 class="wp-block-heading">The Case for Custom Fintech Software</h3>
While generic fintech tools can offer fast implementation and lower upfront costs, they often come with limitations: restricted functionality, poor integration capabilities, and limited scalability. Custom software, on the other hand, is designed around your business model, user requirements, and long-term objectives. It gives you full control over features, design, compliance, and data security.
In sectors like banking, insurance, and asset management—where security, precision, and regulation are critical—custom solutions provide the agility and specificity that standard tools can&#8217;t match.
<h3 class="wp-block-heading">Key Benefits of Custom Solutions</h3>
<h4 class="wp-block-heading">1. Competitive Differentiation</h4>
Custom fintech software allows businesses to introduce unique features, user experiences, and workflows that are hard for competitors to replicate. Whether it&#8217;s a personalized client portal or a proprietary risk assessment tool, the ability to innovate sets you apart in a crowded marketplace.
<h4 class="wp-block-heading">2. Enhanced Data Security &amp; Compliance</h4>
The financial industry operates under intense regulatory scrutiny. Custom solutions can be built to meet specific regulatory requirements (like GDPR, PCI-DSS, or SOX) right from the design phase. You also gain greater control over your data infrastructure, reducing third-party vulnerabilities.
<h4 class="wp-block-heading">3. Seamless Integration</h4>
Most financial businesses rely on a range of systems—from CRMs and ERPs to trading engines and payment gateways. Custom software ensures smooth interoperability with existing infrastructure, eliminating inefficiencies and data silos.
<h4 class="wp-block-heading">4. Scalability and Flexibility</h4>
Off-the-shelf software can be a bottleneck as your business grows. Custom applications, in contrast, are designed with your growth trajectory in mind. You can scale features, expand to new markets, or integrate emerging technologies like blockchain or AI without major overhauls.
<h3 class="wp-block-heading">Key Considerations Before Investing</h3>
<h4 class="wp-block-heading">1. Defining Clear Business Objectives</h4>
Before committing to custom development, it's vital to articulate the problem you&#8217;re solving. Are you improving internal operations? Creating a better customer experience? Meeting a new regulatory mandate? Clear goals will guide the development roadmap and ROI measurement.
<h4 class="wp-block-heading">2. Budgeting Beyond Development</h4>
Many business leaders focus on the initial development cost, overlooking post-launch needs like maintenance, updates, cybersecurity, and user training. A complete financial plan should cover the total cost of ownership over time.
<h4 class="wp-block-heading">3. Choosing the Right Tech Stack</h4>
Your choice of programming languages, frameworks, and databases will influence the software&#8217;s performance, scalability, and maintainability. Consult with experienced architects and make decisions that align with your long-term business and technology strategy.
<h4 class="wp-block-heading">4. Selecting a Development Partner</h4>
Partnering with a trustworthy and skilled software development company is one of the most critical decisions in this journey. If your business operates across Europe, for instance, choosing a software development company in France could offer the dual advantage of EU regulatory familiarity and high engineering standards.
<h3 class="wp-block-heading">Evaluating ROI and Measuring Success</h3>
Custom fintech software is a significant investment, and business leaders must measure returns beyond just revenue. Here are key performance indicators (KPIs) to track:
<ul>
<li>Operational Efficiency: Are you saving time or resources compared to your previous tools?</li>
<li>Customer Satisfaction: Is your client experience more seamless or personalized?</li>
<li>Compliance and Risk Management: Have regulatory issues decreased or become easier to manage?</li>
<li>Market Expansion: Has the software enabled entry into new markets or services?</li>
</ul>
Success also depends on user adoption, system performance, and ongoing innovation. Make sure to gather feedback and iterate quickly.
<h3 class="wp-block-heading">Risks and How to Mitigate Them</h3>
<h4 class="wp-block-heading">1. Scope Creep</h4>
Without a clear scope, development projects can spiral in time and cost. Establish a minimum viable product (MVP) with essential features and follow agile practices to add features iteratively.
<h4 class="wp-block-heading">2. Vendor Dependence</h4>
Custom solutions often tie you to a particular development team. Ensure proper documentation, code ownership rights, and consider source code escrow agreements to protect your business.
<h4 class="wp-block-heading">3. Compliance Gaps</h4>
Working with teams unfamiliar with financial regulations can lead to costly mistakes. Always vet your developers&#8217; experience with industry-specific compliance and certifications.
<h4 class="wp-block-heading">4. Cybersecurity Threats</h4>
Custom doesn't mean immune. Ensure security is built into the development lifecycle with threat modeling, penetration testing, and regular audits.
<h3 class="wp-block-heading">Real-World Use Cases</h3>
<ul>
<li>Wealth Management Firms: Built custom platforms for clients to view portfolios, receive financial advice, and execute trades.</li>
<li>Insurtech Startups: Developed underwriting engines that automate policy issuance based on real-time risk analysis.</li>
<li>Retail Banks: Created mobile apps with AI-powered customer service and personalized financial planning tools.</li>
<li>Crypto Exchanges: Built scalable trading engines with custom compliance modules for different jurisdictions.</li>
</ul>
<h3 class="wp-block-heading">Final Thoughts</h3>
Investing in custom fintech software is not merely a technical decision; it&#8217;s a strategic business move. It allows organizations to respond to market needs faster, offer differentiated value, and maintain compliance in an ever-evolving regulatory landscape.
However, success requires more than capital. It demands vision, planning, and the right partners. For business leaders willing to invest the time and resources, custom fintech solutions can offer an unmatched edge in today&#8217;s technology-driven financial ecosystem.
Whether you&#8217;re a startup entering the fintech space or an established institution looking to modernize, the opportunity to innovate through custom software has never been greater. The key is to approach it strategically—as an investment in your company's future agility, security, and growth.

Investing in Custom Fintech Software: A Strategic Guide for Business Leaders

Wedbush analyst Daniel Ives maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Outperform and lowers the price target from $155 to $140.

DDOG

Wedbush Maintains Outperform on Datadog, Lowers Price Target to $140

Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) stock is trading higher on Wednesday after the company&#8217;s first-quarter 2025 financial results. <a href="https://www.benzinga.com/pressreleases/25/05/g45248070/teva-reports-ninth-consecutive-quarter-of-growth-in-q1-2025-with-key-innovative-medicines-growing-" target="_blank" rel="noreferrer noopener">Here are the details</a>.
Teva reported revenue of $3.89 billion, up 5% year-over-year, missing analyst estimates of $4.00 billion, according to&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
The increase was driven by higher revenues from Austedo in the U.S. segment. Austedo&#8217;s worldwide revenues were $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024.
<ul>
<li>U.S. Austedo revenues increased by 40% to $396 million, mainly due to volume growth, including the approval of Austedo XR, a once-daily pill, in May 2024.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?</a>
Ajovy&#8217;s global revenues were $139 million in Q1 2025, an increase of 26% in local currency terms compared to Q1 2024.
<ul>
<li>US Ajovy&nbsp;revenues were $53 million, an increase of 18% compared to the first quarter of 2024, mainly due to volume growth.</li>
<li>Uzedy&#8217;s global revenues are $39 million in Q1 2025.</li>
<li>The generics business grew across all regions—it increased by 5% in the U.S., 1% in Europe, and 2% in International Markets, all in local currency terms, compared to Q1 2024.</li>
</ul>
The company reported first-quarter adjusted earnings of 52 cents per share, beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimates of 48 cents per share</a>.
Gross profit margin&nbsp;was 48.2% in the first quarter of 2025, compared to 46.4% a year ago, and adjusted gross profit margin&nbsp;was 52.8% compared to 51.4% in the first quarter of 2024.
<ul>
<li>The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products, primarily driven by higher revenues from Austedo, partially offset by a negative impact from foreign exchange rate movements, including hedging effects.</li>
</ul>
Richard Francis, Teva&#8217;s president and CEO, said, &#8220;Now entering the Acceleration Phase of our Pivot to Growth Strategy, we have a clear roadmap to continue Teva&#8217;s transformation into a leading biopharmaceutical company with an expected 30% operating margin, and today have announced ~$700 million net savings by 2027. We&#8217;re accelerating innovative growth and strengthening our generics business, while streamlining our operations, sharpening our business, and optimizing processes. With these results, we are revising our 2025 outlook and reaffirming our 2027 targets.&#8221;
Guidance: Teva Pharmaceutical raises fiscal 2025 adjusted earnings per share from $2.35-$2.65 to $2.45-$2.65 versus the consensus of $2.55.
The generics player narrows 2025 sales guidance from $16.8 billion-$17.4 billion to $16.8 billion-$17.2 billion compared to the consensus of $17.24 billion.
The company said the outlook is based on the existing tariff and trade environment, and does not reflect any policy shifts, including pharmaceutical sector tariffs, that could impact business.
The company increased the Austedo 2025 sales outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.
Teva reaffirmed sales forecasts of $600 million for Ajovy, about $160 million for Uzedy, and approximately $370 million for Copaxone.
Teva also raised operating income guidance from&nbsp;$4.1 billion-$4.6 billion to $4.3 billion-$4.6 billion, with adjusted EBITDA of $4.7 billion-$5.0 billion from $4.5 billion-$5.0 billion.
Price Action: TEVA stock is up 8.2% at $17.48 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45254006/bunge-q1-eps-beats-expectations-cites-tariff-driven-demand-shifts-as-tailwind" target="_blank" rel="noreferrer noopener">Bunge Q1 EPS Beats Expectations, CEO Credits &#8216;Tariff-Related Timing Shifts&#8217; As Tailwind</a></li>
</ul>
Photo: Shutterstock

Health Care

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum

U stock has given up its prior gain. Unity Software shares were trading higher following better-than-expected Q1 financial results.

Press Releases

Doximity to Present at the Jefferies London Healthcare Conference

Doximity Announces Fiscal 2025 Second Quarter Financial Results

Doximity Report Confirms That Telemedicine Serves Key Role in Modern Health Care

Legal

DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Doximity to Release Fiscal 2025 Third Quarter Results on February 6, 2025

Doximity Announces Fiscal 2025 Third Quarter Financial Results

Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fourth Consecutive Year

Doximity to Participate in the Raymond James 46th Annual Institutional Investors Conference

DOXIMITY INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS

Doximity to Release Fiscal 2025 Fourth Quarter and Full Year Results on May 15, 2025

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Claritev Corporation Class A Common Stock

Claritev

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

VSee Health

Waystar Holding

Morgan Stanley

Keybanc

Truist Securities

Mizuho

Goldman Sachs

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)의 주식은 회사가 강력한 4분기 재무 결과를 발표한 후 34.38% 급등했다. 여러 애널리스트들도 <a href="https://www.benzinga.com//node/43543416" target="_blank" rel="noreferrer noopener">목표 주가를 상향 조정</a>했다.
2. 닥시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)의 주식은 회사가 예상보다 나은 3분기 결과를 발표하고 <a href="https://www.benzinga.com//node/43544376" target="_blank" rel="noreferrer noopener">가이던스를 예상치를 상회</a> 발표한 후 34.06% 상승했다.
3. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 엔비디아블랙웰(Blackwell) 랙 스케일 <a href="https://www.benzinga.com//node/43500503" target="_blank" rel="noreferrer noopener">솔루션의 전량 생산 발표</a> 후 27.21% 상승했다.
4. 어펌 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)의 주식은 회사가 긍정적인 2분기 재무 결과를 발표한 후 23.17% 상승했다. <a href="https://www.benzinga.com//node/43566785" target="_blank" rel="noreferrer noopener">애널리스트들이 목표 주가를 상향 조정</a>했다.
5. 핀터레스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>)의 주식은 회사가 예상보다 나은 결과를 발표하고 가이던스를 발표한 후 21.36% 상승했다. <a href="https://www.benzinga.com//node/43546168" target="_blank" rel="noreferrer noopener">예상치를 상회</a>하는 가이던스를 발표했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/pins/analyst-ratings" target="_blank" rel="noreferrer noopener">주식에 대한 목표 주가를 상향 조정</a>했다.
6. 클라우드플레어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>)의 주식은 4분기 재무 결과를 발표한 후 20.42% 상승했다. 여러 애널리스트들이 주식에 대한 <a href="https://www.benzinga.com/quote/net/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 상향 조정</a>했다.
7. 템퍼스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>)의 주식은 TD 코웬의 애널리스트 댄 브레넌(Dan Brennan)이 매수 등급을 재개하고 <a href="https://www.benzinga.com/quote/tem/analyst-ratings" target="_blank" rel="noreferrer noopener">74달러 목표 주가를 발표</a>한 후 20.16% 상승했다.
8. 익스피디아 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)의 주식은 예상보다 나은 4분기 결과를 발표한 후 18.38% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/expe/analyst-ratings" target="_blank" rel="noreferrer noopener">주식에 대한 목표 주가를 상향 조정</a>했다.
9. 스포티파이 테크놀로지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>)의 주식은 회사가 긍정적인 분기 결과를 발표한 후 13.57% 상승했다. <a href="https://www.benzinga.com//node/43506847" target="_blank" rel="noreferrer noopener">애널리스트들이 목표 주가를 상향 조정</a>했다.
10. 모노리식 파워시스템(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)의 주식은 회사가 예상보다 나은 4분기 재무 결과를 발표하고 1분기 매출 전망을 발표한 후 13% 상승했다. 또한, 회사는 분기 배당금을 주당 1.25달러에서 1.56달러로 인상하고 5억 달러의 자사주 매입 프로그램을 발표했다.
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 테바 파마수티컬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)의 주식은 회사와 사노피 SA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)가 <a href="https://www.benzinga.com//node/42531132" target="_blank" rel="noreferrer noopener">궤양성 대장염 및 크론병</a>에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.
2. 클라비요(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)의 주식은 12.85% 급등했다.
3. 올리브 가든 모회사 다덴 레스토랑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>)의 주식은 회사가 예상보다 좋은 2분기 EPS와 <a href="https://www.benzinga.com//node/42585797" target="_blank" rel="noreferrer noopener">2025 회계연도 매출 전망</a>을 발표한 후 12.54% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/dri/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
4. 닥시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)의 주식은 10.91% 상승했다. 스티븐스 앤 컴퍼니(Stephens &amp; Co.)가 중립 등급으로 커버리지를 시작하고 <a href="https://www.benzinga.com/quote/docs/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 $55</a>로 제시했다.
5. 버켄스탁 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>)의 주식은 회사가 예상보다 좋은 4분기 재무 결과와 2025 회계연도 가이던스를 발표한 후 9.70% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/42599431" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
6. 자빌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>)의 주식은 회사가 예상보다 좋은 <a href="https://www.benzinga.com//node/42553094" target="_blank" rel="noreferrer noopener">1분기 EPS와 매출</a>을 발표한 후 7.30% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/jbl/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
7. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 6.88% 상승했다. FDA가 크레네시티(크리네서폰트, crinecerfont) 캡슐과 경구용 용액을 <a href="https://www.benzinga.com//node/42508449" target="_blank" rel="noreferrer noopener">부신피질호르몬 대체 요법 보조 치료제로 승인</a>했다. 이는 4세 이상의 성인 및 소아 환자의 선천성 부신 효소 결핍증(CAH) 치료에 사용된다.
8. 게임스탑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>)의 주식은 지난 주 6.54% 상승했으며, 이는 3분기 실적의 강세가 지속된 결과이다.
9. 닥터 레디스 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>)의 주식은 6.29% 상승했다.
10. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 지난주 6.13% 상승했다.
 
사진 제공: Sundry Photography via Shutterstock


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 도널드 트럼프가 47대 대통령 선거에서 승리한 지난주에 가장 좋은 성과를 냈다.
1. 앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)의 주식은 3분기 실적 발표 후 82.27% 급등했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/41820580" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
2. 탬퍼스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>)의 주식은 엇갈린 3분기 실적과 앰브리 제네틱스(Ambry Genetics) <a href="https://www.benzinga.com//node/41726900" target="_blank" rel="noreferrer noopener">인수 발표</a>로 인해 49.03% 상승했다.
3. 코인베이스 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 45.35% 상승했으며, 이는 투자자들이 <a href="https://www.benzinga.com//node/41810873" target="_blank" rel="noreferrer noopener">트럼프 당선자의 암호화폐 정책</a>을 평가한 것으로 보다.
4. 아스테라 랩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>)의 주식은 3분기 실적이 예상보다 좋게 나타나고 여러 애널리스트들이 <a href="https://www.benzinga.com//node/41755450" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>한 후 42.57% 상승했다.
5. 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)의 주식은 회사가 예상보다 좋은 재무 실적을 발표하고 가이던스를 <a href="https://www.benzinga.com//node/41856961" target="_blank" rel="noreferrer noopener">컨센서스 이상으로 발표한</a> 후 41.0% 급등했다.
6. 엑슨 엔터프라이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>)의 주식은 3분기 실적과 <a href="https://www.benzinga.com//node/41823452" target="_blank" rel="noreferrer noopener">예상 이상의 가이던스 발표</a> 후 39.76% 상승했다.
7. 닥시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41829467" target="_blank" rel="noreferrer noopener">강력한 2분기 실적</a>을 발표한 후 39.29% 상승했다.
8. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 도널드 트럼프가 2024년 대통령 선거에서 승리한 후 지속적인 강세로 32.28% 상승했다. 이는 일론 머스크의 캠페인 지지와 <a href="https://www.benzinga.com//node/41813356" target="_blank" rel="noreferrer noopener">그가 행정부의 일원이 될 것이라는 기대</a> 때문일 수 있다.
9. 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 주식은 트럼프의 <a href="https://www.benzinga.com//node/41793048" target="_blank" rel="noreferrer noopener">미국 대통령 선거 승리</a> 소식에 25.58% 상승했다.
10. 레딧(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>)의 주식은 <a href="https://www.benzinga.com//node/41773982" target="_blank" rel="noreferrer noopener">선거 결과 발표</a> 후 23.64% 상승했다.
 
사진 출처: Shutterstock


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

닥시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)의 주식은 회사가 예상보다 좋은 <a href="https://www.benzinga.com/pressreleases/24/11/b41823433/doximity-announces-fiscal-2025-second-quarter-financial-results"> 2분기 재무 결과</a>를 발표한 후 목요일 애프터 마켓 세션에서 37% 이상 급등했다.
<ul>
<li>Q2 매출: 1억 3,683만 달러, <a href="https://www.benzinga.com/calendars/earnings">예상치</a> 1억 2,715만 달러 대비 상회</li>
</ul>
<ul>
<li>Q2 조정 EPS: 30센트, 예상치 25센트 대비 상회</li>
</ul>
매출은 전년 대비 20% 증가했다. 이 회사는 2분기 동안 6,830만 달러의 영업 현금 흐름과 6,680만 달러의 잉여 현금 흐름을 생성했다. 잉여 현금 흐름은 전년 대비 475% 증가했다.
&#8220;우리의 임상 워크플로우 도구는 2분기에 600,000명 이상의 고유한 활성 처방자가 기록적으로 사용했다. 우리는 의사들이 시간을 절약해 더 나은 환자 치료를 제공할 수 있도록 도와주게 되어 자랑스럽다&#8221;라고 닥시미티의 공동 창립자이자 CEO인 제프 탕네이(Jeff Tangney)가 말했다.
가이던스: 닥시미티는 3분기 매출이 1억 5,200만 달러에서 1억 5,300만 달러 사이가 될 것으로 예상하고 있다. 이 회사는 3분기 조정 EBITDA가 8,300만 달러에서 8,400만 달러 사이가 될 것으로 예상하고 있다.
닥시미티는 연간 매출이 5억 3,500만 달러에서 5억 4,000만 달러 사이가 될 것으로 보고 있다. 이 회사는 연간 조정 EBITDA가 2억 7,400만 달러에서 2억 7,900만 달러 사이가 될 것으로 예상하고 있다.
DOCS 주가 동향: 닥시미티의 <a href="https://www.benzinga.com/quote/DOCS" target="_blank" rel="noreferrer noopener">주식</a>은 목요일 애프터 마켓에서 37.95% 상승한 59.90달러에 거래되었다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41828399/fortinet-q3-earnings-revenue-beat-eps-beat-billings-up-6-shares-slide">포티넷 3분기 실적: 매출 초과, EPS 초과, 청구액 6% 증가, 주가 하락</a></li>
</ul>
사진: Doximity 제공.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

After-Hours Center

닥시미티의 주식은 강력한 2분기 실적을 발표한 후 시간외 거래에서 37% 이상 급등

금요일 아침 (현지 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<ul>
<li>월스트리트는 에코스타 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>)이 개장 전에 39억 8천만 달러의 매출과 주당 25센트의 분기 손실을 보고할 것으로 예상하고 있다. 에코스타의 주가는 시간외 거래에서 0.4% 하락한 20.00달러를 기록했다.</li>
<li>테이크투 인터랙티브 소프트웨어(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>)가 회계연도 <a href="https://kr.benzinga.com/news/usa/stocks/%ed%85%8c%ec%9d%b4%ed%81%ac%ed%88%ac-%ec%9d%b8%ed%84%b0%eb%9e%99%ed%8b%b0%eb%b8%8c%ec%9d%98-%ec%a3%bc%ec%8b%9d%ec%9d%80-1%eb%b6%84%ea%b8%b0-%ec%8b%a4%ec%a0%81%ea%b3%bc-2%eb%b6%84%ea%b8%b0-%ec%a0%84/" target="_blank" rel="noopener">1분기 재무 결과 발표</a>한 후 시간외 거래에서 주가가 올랐다. 이 회사는 1분기 매출이 전년 동기 대비 5% 증가한 13억 4천만 달러를 기록했다고 밝혔다. 순 예약은 12억 2천만 달러로 전년 대비 1% 증가했다. 테이크투의 주가는 시간외 거래에서 5.3% 상승한 146.13달러를 기록했다.</li>
<li>분석가들은 아메리칸 엑슬 앤 메뉴펙처링(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>)이 매출 15억 8천만 달러에 주당 11센트의 분기 이익을 기록할 것으로 예상하고 있다. 이 회사는 개장 전에 실적을 발표할 예정이다. 아메리칸 엑슬의 주식은 시간외 거래에서 0.3% 상승한 6.23달러를 기록했다.</li>
</ul>
당사의 <a href="https://www.benzinga.com/premarket/">프리마켓 개요는 이곳</a>
<ul>
<li>닥시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)는 예상보다 나은 <a href="https://kr.benzinga.com/news/usa/stocks/%eb%8b%a5%ec%8b%9c%eb%af%b8%ed%8b%b0%ec%9d%98-%ec%a3%bc%ec%8b%9d%ec%9d%80-%ec%98%88%ec%83%81%eb%b3%b4%eb%8b%a4-%ec%a2%8b%ec%9d%80-1%eb%b6%84%ea%b8%b0-%eb%a7%a4%ec%b6%9c%ea%b3%bc-%ec%88%9c%ec%9d%b4/" target="_blank" rel="noopener">1분기 재무 실적</a>을 보고하고 강력한 FY24 매출 지침을 발표했다. Benzinga Pro에 따르면 닥시미티의 1분기 매출은 전년 동기 대비 17% 증가한 1억 2,668만 달러로 컨센서스 추정치 1억 1,992만 달러를 넘어섰다. 이 회사는 주당 28센트의 조정 이익을 보고했는데, 이는 애널리스트 추정치인 주당 22센트를 뛰어넘는 수치이다. 닥시미티의 주가는 시간외 거래에서 28.5% 상승한 32.97달러를 기록했다.</li>
<li>분석가들은 AMC 네트웍스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>)가 개장 전에 6억 134만 달러의 매출과 분기 이익을 주당 1.52달러로 기록할 것으로 예상한다. AMC 네트웍스의 주가는 시간외 거래에서 0.4% 상승한 10.34달러를 기록했다.</li>
</ul>
사진제공: 테이크 투 인터랙티브
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Pre-Market Outlook

Markets

AMCX

SATS

TTWO

금요일 주목해야 할 주식: 테이크투 인터랙티브, 에코스타, 닥시미티 그리고 2종목

닥시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)는 목요일 시장 마감 후 회계연도 1분기 재무 결과를 발표했다. 이 발표로 주가는 시간외 거래에서 28% 이상 상승했다. 이번 분기의 <a href="https://www.benzinga.com/pressreleases/24/08/b40265858/doximity-announces-fiscal-2025-first-quarter-financial-results">주요 지표</a>는 다음과 같다.
어떤 일이 (What Happened): 의료 전문가들을 위한 온라인 네트워킹 서비스를 제공하는 닥시미티의 1분기 매출은 전년 동기 대비 17% 증가한 1억 2,668만 달러로, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">합의 추정치</a>인 1억 1,992만 달러를 넘어섰다. 이 회사는 주당 28센트의 조정 이익을 보고했는데, 이는 분석가 추정치인 주당 22센트를 뛰어넘는 수치이다.
닥시미티는 전년 대비 28% 감소한 4,120만 달러의 영업 현금 흐름과 전년 대비 29% 감소한 3,950만 달러의 잉여 현금 흐름을 창출했다.
닥시미티의 공동 창립자이자 CEO인 제프 탕네이(Jeff Tangney)는 &#8220;지난 분기에 매출과 순익 모두를 달성하면서 강력한 수익과 기록적인 참여를 제공하게 되어 기뻤다&#8221;고 말했다. &#8220;지난 분기에는 기록적인 590,000명의 의료 제공자가 시간을 절약하고 환자에게 더 나은 서비스를 제공하기 위해 AI, 원격 의료, 메시징 및 예약 워크플로 도구를 사용했다.&#8221;
닥시미티는 2분기 매출이 추정치 1억 2,395만 달러 대비 1억 2,650만 ~ 1억 2,750만 달러에 이를 것으로 예상한다. 닥시미티는 2025년 연간 매출을 5억 1,400만 달러에서 5억 2,300만 달러로 예상하고 있으며 추정치는 5억 1,229만 달러이다.
닥시미티는 1분기 조정 EBITDA를 6,250만~6,350만 달러로 예상한다. 이 회사는 연간 조정 EBITDA를 2억 4,850만 달러에서 2억 5,750만 달러로 예상한다.
DOCS 주가 움직임: 닥시미티의 주식은 목요일 애프터마켓에서 28.49% 상승한 32.98달러를 기록했다.
사진: Doximity에서 제공함
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

닥시미티의 주식은 예상보다 좋은 1분기 매출과 순이익으로 시간외 거래에서 급등

금요일 오전 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같습니다:
<ul>
<li><a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 월스트리트는 RBC 베어링스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>)가 개장 전 4억 1,351만 달러의 매출과 주당 2.36달러의 분기 이익을 보고할 것으로 예상하고 있다. RBC 베어링스의 주가는 시간외 거래에서 1% 하락한 265.00달러를 기록했다</li>
<li>어플라이드 머티어리얼즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)는 목요일에 예상보다 나은 2분기 재무 결과를 보고했다. 이 회사는 3분기 매출이 66억 5천만 달러(+/-4억 달러)로 추정치인 65억 7,600만 달러와 대조된다고 밝혔다. 이 회사는 3분기 조정 수익이 주당 1.98달러에서 주당 1.83달러에서 2.19달러 사이가 될 것으로 예상하고 있다. 어플라이드 머티어리얼즈 주가는 시간외 거래에서 1.2% 하락한 211.51달러를 기록했다.</li>
<li>애널리스트들은 화주호텔 그룹(H World Group)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>)가 주당 28센트, 매출 7.115억 달러의 1분기 실적을 발표할 것으로 예상하고 있다. 이 회사는 시장 개장 전에 실적을 발표할 예정이다. 시간외 거래에서 화주호텔 그룹의 주식은 2.3% 상승한 43.00달러에 거래됐다.</li>
</ul>
여기서 <a href="https://www.benzinga.com/premarket/">개장 전 시황 요약 확인하기</a>
<ul>
<li>독시미티(NYSE:<a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)는 목요일에 예상보다 강한 4분기 재무 결과를 보고했다. 이 회사는 1분기 매출이 1억 1,950만 달러에서 1억 2,050만 달러 사이가 될 것으로 예상한다고 밝혔다. 이는 추정치 1억 1,923만 달러와 비교된다. 독시미티의 주가는 시간외 거래에서 15.8% 상승한 27.48달러를 기록했다. </li>
<li>분석가들은 RLX 테크놀로지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>)가 개장 전에 7,411만 달러의 매출에 주당 2센트의 분기 이익을 게시할 것으로 예상한다. RLX 테크놀로지의 주가는 시간외 거래에서 0.9% 상승한 2.1698달러를 기록했다.</li>
</ul>
유용한 정보: <a href="https://www.benzinga.com/news/24/05/38872018/top-5-utilities-stocks-you-may-want-to-dump-in-may">5월에 처분하고 싶은 상위 5가지 유틸리티 주식</a>

AMAT

HTHT

RBC 베어링스, 어플라이드 머티어리얼즈 그리고 금요일 주목해야 할 3개의 주식

독시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)는 목요일 시장 마감 후에 2024 회계연도 4분기 재무 결과를 보고했다. 이번 분기의 <a href="https://www.benzinga.com/pressreleases/24/05/b38882790/doximity-announces-fourth-quarter-and-fiscal-year-2024-financial-results">주요 하이라이트</a>를 살펴보자. 이 회사는 미국에서 의료 전문가를 위한 클라우드 기반 디지털 플랫폼을 운영하고 있다.
4분기 실적: <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">벤징가 프로</a>에 따르면 독시미티의 4분기 매출은 전년 동기 대비 6% 증가한 1억 1,810만 달러로 합의 추정치인 1억 1,640만 달러를 넘어섰다. 이 회사는 주당 25센트의 조정 이익을 보고했는데, 이는 분석가의 주당 20센트 추정치를 뛰어넘는 수치이다.
독시미티는 전년 대비 37% 증가한 6,390만 달러의 영업 현금 흐름을 창출했다. 잉여 현금 흐름도 전년 대비 37% 증가한 6,230만 달러를 기록했다.
독시미티의 공동 창립자이자 CEO인 제프 탕네이(Jeff Tangney)는 &#8220;우리는 또 다른 분기에 걸쳐 높은 수익과 기록적인 참여를 달성하면서 매출과 및 순익이 예상을 넘어서 기뻤다&#8221;고 말했다. "지난 분기에 580,000명이 넘는 고유 제공업체들이 우리의 워크플로 도구를 사용하면서 임상 워크플로에 AI와 자동화를 도입하게 된 것을 자랑스럽게 생각다."
독시미티는 이사회가 5월 1일에 회사 보통주 최대 5억 달러의 환매 프로그램을 승인했음을 강조했다. 이 회사는 모든 이전 환매 프로그램이 2024년 4월 기준 완료되었다고 언급했다.
전망 (Outlook): 독시미티는 1분기 매출이 1억 1,950만 달러에서 1억 2,050만 달러 사이가 될 것으로 예상하고 있으며, 이는 추정치 1억 1,923만 달러에 비해 높은 수치이다. <a href="http://pro.benzinga.com">Benzinga Pro</a>에 따르면 연간 매출은 5억 600만 달러에서 5억 1,800만 달러 사이로 예상되며 추정치는 5억 2,077만 2,000달러이다.
독시미티는 또한 1분기 조정 EBITDA를 5,500만 달러에서 6,500만 달러로, 연간 조정 EBITDA를 2억 3,800만 달러에서 2억 5,000만 달러로 안내했다.
DOCS 주가 움직임:  독시미티의 주가는 시간외 거에서 15.75% 상승한 27.48달러에 거래되었다.
사진: Doximity 제공

독시미티: 예상보다 좋은 4분기 매출과 순이익으로 주가 15% 이상 급등

Comments

Doximity

뉴스

에 대한 최신 뉴스 Doximity (NYSE:DOCS) 주식

일요일, 2월 09, 2025

일요일, 12월 22, 2024

월요일, 11월 11, 2024

목요일, 11월 07, 2024

금요일, 8월 09, 2024

금요일, 5월 17, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌